Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2017-09-04 Transaction in Own Shar…
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 88% confidence The text describes share repurchases (“purchased an accumulated 5,286,871 shares … under the stock buyback program”) and is a notice of transactions in the company’s own shares. This matches the “Transaction in Own Shares” category (POS).
2017-09-04 English
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement about Novozymes' share buy-back program, including transaction volumes, prices, and dates. It references the company's repurchase of its own shares under a specific program and provides detailed trading data. There is no indication of financial statements, earnings data, or management discussion. The content focuses on the company's transactions in its own shares, consistent with a share repurchase report. Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement but a substantive report on share buy-back transactions.
2017-09-04 English
Transaction in Own Shares 2017
Transaction in Own Shares Classification · 100% confidence The document text explicitly states that Novozymes has purchased an accumulated number of shares under a 'stock buyback program' initiated on January 25, 2017. This action directly relates to the company acquiring its own shares, which corresponds to the definition of 'Transaction in Own Shares'. The document is very short (281 characters) and directs the reader to a PDF for the full announcement, but the core content is a specific transaction type, making POS a more precise classification than RPA or RNS, although RPA might be applicable if this were purely a notice *about* the transaction report. Given the direct reporting of the buyback activity, POS is the best fit.
2017-08-28 English
Transaction in Own Shares 2017
Transaction in Own Shares Classification · 100% confidence The document text is very short (267 characters) and explicitly states that Novozymes bought back a specific number of shares under a previously announced share repurchase program. The final line, 'Læs hele meddelelsen i PDF format' (Read the full announcement in PDF format), strongly suggests this is a brief notification about a transaction rather than the full regulatory filing detailing the transaction. This aligns best with the 'Transaction in Own Shares' category (POS), which covers share repurchase reports. It is not an announcement of a report (RPA/RNS) because it contains substantive transaction data, but the core subject is the share repurchase itself.
2017-08-28 Danish
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement of transactions related to Novozymes' share buy-back program, including specific dates, number of shares bought, prices, and total transaction values. It references compliance with EU regulations on market abuse and provides detailed trading data. There is no indication of financial statements, earnings data, management discussion, or other report content. The document is focused on the company's repurchase of its own shares, which fits the category of a share repurchase announcement. Given the detailed transactional data and the nature of the content, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement or a simple notification but a full transaction report.
2017-08-28 English
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement of transactions under Novozymes' stock buyback program, including number of shares purchased, transaction values, and dates. It references compliance with Market Abuse Regulation and provides detailed trading data. There is no indication of financial statements, management discussion, or earnings data. The content is focused on the company's repurchase of its own shares, which fits the category of a share repurchase or issuance announcement. Therefore, the document is best classified as a Transaction in Own Shares (POS) filing.
2017-08-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.